Anaut develops EUREKA, a series of AI medical devices that analyze surgical video in real time to support surgeons' vision. EUREKA α uses deep learning on endoscopic and robotic surgery images to highlight structures such as loose connective tissue and nerves. It received Japanese manufacturing and sales approval on April 12, 2024. The company set up Anaut America in 2025, planned a European subsidiary, and is pursuing FDA and CE approvals.
Builder’s Brief
Anaut is a healthcare tool on Falcoscan. EUREKA surgical AI highlights hard-to-see anatomy in real time during surgery. Falcoscan rates Anaut with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. Anaut is founded in 2020, currently at Series_b stage. Pricing: Paid.
Market position · Healthcare
How Anaut compares in Healthcare
Anaut's opportunity score of 84 ranks #37 of 137 live Healthcare tools on Falcoscan, 2.2 points above the category average of 81.8. Its saturation score is 11/100, against a category average of 11. 75 of the 137 live Healthcare tools carry a hot signal, and Falcoscan has recorded 8 shutdowns in the category.
The top-rated live Healthcare tools on Falcoscan, other than Anaut, are DeepMind AlphaFold, Nuance DAX Copilot, Viz.ai AI Stroke Response, Tempus AI Diagnostics, and Viz.ai Stroke AI.
Is Anaut still operating?
Yes. Falcoscan's operating checks list Anaut as active.